Apimeds Pharmaceuticals US, Inc. (APUS) — Tangible Net Worth Ratio
Apimeds Pharmaceuticals US, Inc. (APUS) has a Tangible Net Worth Ratio of 100.0% as of March 2026. This metric is calculated by deducting intangible assets ($0.00) from net assets ($126.52 Million) and expressing it as a percentage of total net assets. A higher ratio means that more of the company's equity is backed by tangible, balance-sheet-verifiable assets rather than goodwill, patents, or brand value. Also explore Apimeds Pharmaceuticals US, Inc. (APUS) net asset momentum to track the company's year-over-year net asset growth rate.
Tangible NW Ratio
Net Assets (Equity)
Intangible Assets
Total Assets
Apimeds Pharmaceuticals US, Inc. Tangible Net Worth Ratio (2023–2025)
This chart shows how Apimeds Pharmaceuticals US, Inc.'s Tangible Net Worth Ratio has changed across 2 annual periods from 2023 to 2025. As of March 2026, the ratio stands at 100.0%, reflecting net assets of $126.52 Million with intangible assets of $0.00 USD. For live market cap and overall valuation, see Apimeds Pharmaceuticals US, Inc. stock valuation.
Annual Tangible Net Worth Ratio for Apimeds Pharmaceuticals US, Inc. (2023–2025)
The table below presents the year-by-year Tangible Net Worth Ratio for Apimeds Pharmaceuticals US, Inc. from 2023 to 2025, covering 2 annual filings. Each row shows net assets, intangible assets, total assets, the tangible net worth ratio, and the change in percentage points versus the prior year. See APUS financial flexibility index to measure the company's free cash flow as a share of total liabilities.
| Year | Tangible NW Ratio | Net Assets (USD) | Intangible Assets | Total Assets | Change (pp) |
|---|---|---|---|---|---|
| 2025 | 100.0% | $153.35 Million | $0.00 | $164.18 Million | ▲ +0.0 pp |
| 2023 | 100.0% | $31.87K | $0.00 | $422.08K | — |